Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) released its financial results for the first three quarters of 2026, reporting operating revenue of RMB 30.463 billion, up 5.81% year-on-year (at constant exchange rates, the same below), driven by continuous revenue growth from innovative drugs.
Financial Performance – 9M 2026
| Metric | 9M 2026 | YoY Change |
|---|---|---|
| Operating Revenue | RMB 30.463 billion | +5.81% |
| Net Profit Attributable to Shareholders of the Parent | RMB 2.667 billion | +5.71% |
| Net Profit After Deducting Non-Recurring Gains and Losses | RMB 1.706 billion | +8.42% |
Profit growth was driven by the continuous revenue growth from innovative drugs, with the faster expansion of deducted (non-recurring-adjusted) net profit — +8.42% — underscoring improving core earnings quality.
R&D Investment
| Metric | 9M 2026 | YoY Change |
|---|---|---|
| Total R&D Expenditure | RMB 5.247 billion | +31.24% |
| R&D Expenses | RMB 3.118 billion | +14.21% |
| R&D Expenditure on Innovative Drugs | RMB 4.346 billion | +55.07% |
Innovative-drug R&D accounted for the overwhelming majority of total R&D expenditure, reflecting the company’s decisive shift of resources toward its innovation pipeline.
Pipeline & Strategy
- Global Phase III Momentum: Multiple blockbuster products have entered or gradually initiated global multi-center Phase III clinical trials.
- Strategic In-Licensing: The company successfully in-licensed near-commercialization innovative pipelines including GR1803 and JS005, further enriching and optimizing its core pipeline portfolio while strengthening commercialization certainty for upcoming products.
- Core Therapeutic Areas: Fosun Pharma remains focused on oncology, immune inflammation, and neurodegenerative diseases, with innovative achievements rapidly coming to fruition.
- Approval Track Record: In 9M 2026, a total of 22 indications across 8 innovative drugs were approved for marketing.
- Solid Tumor Synergy: In lung cancer, breast cancer, and gastrointestinal tumors, multi-product synergy and global commercialization have fostered a differentiated competitive advantage.
Market Impact & Outlook
- Innovation-Led Growth Model: The 9M results validate Fosun Pharma’s transition from a diversified healthcare conglomerate toward an innovation-driven pharmaceutical core, with innovative drug revenue now the primary earnings engine.
- R&D Intensity Acceleration: A 55.07% surge in innovative-drug R&D expenditure signals aggressive pipeline buildout aimed at sustaining medium-term growth, at the cost of near-term expense pressure.
- Commercial Certainty: In-licensing near-commercialization assets (GR1803, JS005) shortens the path from pipeline to revenue, complementing internally developed global Phase III programs.
- Outlook Details: Full-year guidance, segment-level revenue breakdowns, and geographic splits were not disclosed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Fosun Pharma’s pipeline development, clinical trial progress, product commercialization, and financial performance. Actual results may differ materially due to risks including clinical trial outcomes, regulatory approval timelines, market competition, reimbursement and pricing policy changes, and foreign exchange fluctuations.-Fineline Info & Tech
